Chief Accounting Officer Gertsch Timothy covered exercise/tax liability with 405 shares, decreasing direct ownership by 0.69% to 57,947 units (SEC Form 4)

$AGL
Misc Health and Biotechnology Services
Health Care
Get the next $AGL alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gertsch Timothy

(Last) (First) (Middle)
C/O AGILON HEALTH, INC.
6210 E HWY 290, SUITE 450

(Street)
AUSTIN TX 78723

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
agilon health, inc. [ AGL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Accounting Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/16/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/16/2024 F 405(1) D $4.85 57,947(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the restricted stock units and does not represent a sale.
2. Includes restricted stock units.
Remarks:
/s/ Denise Zamore, as Attorney-in-Fact 08/20/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $AGL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AGL

DatePrice TargetRatingAnalyst
1/10/2025$1.75 → $2.25Sell → Neutral
Citigroup
1/10/2025Hold
Needham
12/16/2024Neutral
Macquarie
12/11/2024$2.50Mkt Perform
Bernstein
11/11/2024Mkt Outperform → Mkt Perform
JMP Securities
11/8/2024Outperform → Mkt Perform
William Blair
10/30/2024$7.00 → $2.50Neutral → Sell
Citigroup
10/2/2024$3.00Buy → Underperform
BofA Securities
More analyst ratings

$AGL
Press Releases

Fastest customizable press release news feed in the world

See more
  • agilon health to Participate in TD Cowen's 45th Annual Health Care Conference

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health in our communities, announced that it will participate in the 45th Annual TD Cowen Healthcare Conference including a fireside chat presentation on Wednesday, March 5 at 9:50 AM Eastern Time. Interested investors and other parties may listen to a simultaneous webcast of the presentation by visiting the "Events & Presentations" section of agilon health's investor relations website at https://investors.agilonhealth.com. Replays will be available for on-demand listening shortly after the completion of the presentation. About agilon health agilon health is the trusted partner empowering physicians to

    $AGL
    Misc Health and Biotechnology Services
    Health Care
  • agilon health Sets Date to Report Fourth Quarter and Full Year 2024 Financial Results

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health in our communities, announced that it will release its financial results for the fourth quarter and full year 2024 after the market closes on Tuesday February 25, 2025, and host a conference call at 4:30 PM Eastern Time the same day to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 599648. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A

    $AGL
    Misc Health and Biotechnology Services
    Health Care
  • agilon health Reports Third Quarter 2024 Results

    Revenue increased 28% to $1.45 billion, Medicare Advantage membership increased 37% to 525,000, and total members on the agilon platform grew 39% to 657,000 Third quarter results were affected by lower-than-expected 2024 risk adjustment, negative prior year development mainly from risk adjustment and Part D, and higher current year medical expenses Adjusted full year guidance reflects Q3 results and updated Q4 cost trends agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, today announced results for the third quarter ended September 30, 2024. "Our full-risk model enables primary care physicians to deliver high-quality c

    $AGL
    Misc Health and Biotechnology Services
    Health Care

$AGL
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$AGL
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$AGL
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$AGL
SEC Filings

See more

$AGL
Leadership Updates

Live Leadership Updates

See more
  • agilon health Appoints Karthik Rao, M.D., as Chief Medical Officer

    Dr. Rao to Continue to Lead Clinical Strategy and Drive Physician Network Performance Alongside agilon's Chief Clinical Officer Kevin Spencer, M.D. agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that after a comprehensive search Karthik Rao, M.D., who has served as agilon's interim chief medical officer (CMO) since February 2024, has been appointed to the permanent CMO role, effective immediately. He previously served as senior medical director and vice president, network performance, at the company. Prior to joining agilon in 2022, Dr. Rao held several roles in value-based care, including nearly a d

    $AGL
    Misc Health and Biotechnology Services
    Health Care
  • agilon health Names Jeff Schwaneke New Chief Financial Officer

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that Jeff Schwaneke, an experienced finance, operational and managed care executive and director on agilon's board, will join the Company as chief financial officer and executive vice president effective July 1, 2024. He will be a member of agilon's Executive Leadership team reporting to chief executive officer (CEO), Steve Sell. Schwaneke succeeds Timothy Bensley, who announced his retirement from agilon in early 2024. Bensley has agreed to stay on through a transition period. Schwaneke was most recently executive vice president, Health Care Enterprises,

    $AGL
    Misc Health and Biotechnology Services
    Health Care
  • agilon health, inc. investors: Please contact the Portnoy Law Firm to recover your losses; May 28, 2024 deadline

    Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, May 13, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises agilon health, inc. (NYSE:AGL) investors that a lawsuit was filed on behalf of investors that purchased agilon securities between April 15, 2021 and February 27, 2024, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to

    $AGL
    Misc Health and Biotechnology Services
    Health Care

$AGL
Financials

Live finance-specific insights

See more
  • agilon health Sets Date to Report Fourth Quarter and Full Year 2024 Financial Results

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health in our communities, announced that it will release its financial results for the fourth quarter and full year 2024 after the market closes on Tuesday February 25, 2025, and host a conference call at 4:30 PM Eastern Time the same day to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 599648. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A

    $AGL
    Misc Health and Biotechnology Services
    Health Care
  • agilon health Reports Third Quarter 2024 Results

    Revenue increased 28% to $1.45 billion, Medicare Advantage membership increased 37% to 525,000, and total members on the agilon platform grew 39% to 657,000 Third quarter results were affected by lower-than-expected 2024 risk adjustment, negative prior year development mainly from risk adjustment and Part D, and higher current year medical expenses Adjusted full year guidance reflects Q3 results and updated Q4 cost trends agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, today announced results for the third quarter ended September 30, 2024. "Our full-risk model enables primary care physicians to deliver high-quality c

    $AGL
    Misc Health and Biotechnology Services
    Health Care
  • agilon health Sets Date to Report Third Quarter 2024 Financial Results

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced that it will release its financial results for the third quarter 2024 after the market closes on Thursday, November 7, 2024, and host a conference call at 4:30 PM Eastern Time the same day to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 520026. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of

    $AGL
    Misc Health and Biotechnology Services
    Health Care

$AGL
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more